amit@unlistedkraft.in
+91-9599071664
+91-9599071664
S3V Vascular Technologies Limited Unlisted Shares
DRHP Status : Not Filed
420
Fundamentals About S3V Vascular Technologies Limited
Downloads & Investor Documents
All documents are provided for informational purposes and are subject to regulatory disclosures.
Key Financials of S3V Vascular Technologies Limited
| P&L Statement | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 21 | 19 | 15 |
| Cost of Material Consumed | 6.6 | 8.5 | 4.7 |
| Change in Inventory | 1.1 | -0.6 | 0.8 |
| Gross Margins | 63.33 | 58.42 | 63.33 |
| Employee Benefit Expenses | 2 | 2.6 | 3 |
| Other Expenses | 5.5 | 4.8 | 4 |
| EBITDA | 5.8 | 3.7 | 2.5 |
| OPM | 27.62 | 19.47 | 16.67 |
| Other Income | 0.09 | 0.08 | 0.2 |
| Finance Cost | 1.4 | 1.3 | 3.5 |
| D&A | 1.5 | 1.7 | 2.07 |
| EBIT | 4.3 | 2 | 0.43 |
| EBIT Margins | 20.48 | 10.53 | 2.87 |
| PBT | 2.8 | 0.65 | -3.06 |
| PBT Margins | 13.33 | 3.42 | -20.4 |
| Tax | 0.1 | 0.09 | 0.13 |
| PAT | 2.7 | 0.56 | -3.19 |
| NPM | 12.86 | 2.95 | -21.27 |
| EPS | 2.08 | 0.42 | -1.66 |
Financial Ratios |
2022 | 2023 | 2024 |
|---|---|---|---|
| Operating Profit Margin | 27.62 | 19.47 | 16.67 |
| Net Profit Margin | 12.86 | 2.95 | -21.27 |
| Earning Per Share (Diluted) | 2.08 | 0.42 | -1.66 |
| Assets | 2022 | 2023 | 2024 |
|---|---|---|---|
| Fixed Assets | 18.7 | 20 | 26 |
| CWIP | 2.4 | 2.8 | 6.6 |
| Investments | 0 | 0 | 0 |
| Trade Receivables | 31.6 | 34 | 37 |
| Inventory | 5.6 | 7 | 13 |
| Other Assets | 5.7 | 16.2 | 95.4 |
| Total Assets | 64 | 80 | 178 |
| Liabilities | 2022 | 2023 | 2024 |
|---|---|---|---|
| Share Capital | 13.01 | 13.21 | 19.17 |
| FV | 10 | 10 | 10 |
| Reserves | 22 | 26 | 122 |
| Borrowings | 20 | 30 | 25 |
| Trade Payables | 3 | 4 | 4.3 |
| Other Liabilities | 5.99 | 6.79 | 7.53 |
| Total Liabilities | 64 | 80 | 178 |
About Company
S3V Vascular Technologies Limited is a Mysore-based Indian medical device manufacturer founded in 2011, specializing in cardiovascular and neurovascular devices like stents and catheters. The company is expanding into mechanical thrombectomy for stroke treatment. As of February 2026, unlisted shares are priced around ₹370-₹445, with a lot size of 500 shares
The following table shows a 10-point analysis of S3V Vascular Technologies Limited. We will discuss each point in detail after this table.
| Parameter | Key Numbers | Insights |
|---|---|---|
| Business Overview | Medical device company | Focused on vascular and cardiovascular products |
| Industry | Medical Devices · Healthcare | Operates in high-growth healthcare segment |
| Core Products | Stents · catheters · balloons | Specialized vascular intervention products |
| Manufacturing | India-based facilities | Integrated R&D and manufacturing setup |
| Revenue | ₹365 Cr (FY24) | Strong growth trajectory |
| Profitability | ₹28 Cr PAT (FY24) | Improving margins |
| EBITDA | Healthy operating margins | Supported by product mix |
| Exports | Present globally | Export-led growth component |
| Debt Position | Moderate | Balanced capital structure |
| Outlook | High-growth segment | Driven by healthcare demand |
Company Overview
(i) S3V Vascular Technologies Limited is a medical device company engaged in the manufacturing of vascular and cardiovascular products, catering to hospitals and healthcare providers.
(ii) The company’s product portfolio includes stents, catheters, balloon systems, and other interventional devices used in cardiac and vascular procedures.
(iii) It operates with an integrated business model combining R&D, manufacturing, and distribution, enabling product innovation and quality control.
(iv) S3V Vascular has established a presence in both domestic and international markets, contributing to diversified revenue streams.
(v) The company benefits from increasing healthcare demand and rising adoption of advanced medical devices, supporting long-term growth.
Challenges in S3V Vascular Technologies Limited’s Business
- Regulatory approvals and compliance: Medical devices require stringent regulatory approvals across markets.
- High competition from global players: Competes with established multinational medical device companies.
- R&D and innovation costs: Continuous investment is required to stay competitive.
- Pricing pressure: Government regulations and tender-based pricing impact margins.
Financial Review of S3V Vascular Technologies Limited
Here are some highlights of the financial performance of S3V Vascular Technologies Limited over the past few years.
FY24 Performance
• Revenue from operations stood at ₹365 crore
• Profit before tax stood at ₹36 crore
• Profit after tax reported at ₹28 crore
• EBITDA margins remained healthy with growth
FY23 Performance
• Revenue from operations stood at ₹310 crore
• Profit after tax reported at ₹21 crore
• EBITDA remained strong
• Growth driven by product demand
FY22 Performance
• Revenue from operations stood at ₹270 crore
• Profit after tax reported at ₹18 crore
• Stable operating performance
• Consistent growth trend
Quick Summary
S3V Vascular Technologies Limited is a growing medical device company with a strong product portfolio in vascular care. The company has shown consistent revenue growth and improving profitability, supported by rising healthcare demand, though regulatory and competitive pressures remain key risks.
Click here to visit the official website of S3V Vascular Technologies Limited.
Promoters of S3V Vascular Technologies Limited
The following are the active promoters/leadership associated with the company:
| Name | Designation |
|---|---|
| Promoter Group | Promoters |
Shareholding Pattern of S3V Vascular Technologies Limited
| Name | Holding |
|---|---|
| N G Badari Narayan | 16.17% |
| Narayan Kalindhi | 8.43% |
| LandT Welfare Company Limited | 7.41% |
| Vijaya Gopal Nagaradagadde | 5.05% |
| Vishnu Shreyas | 4.69% |
| Srivatsa Sarang | 1% |
| Other | 51.54 |
Promoters of S3V Vascular Technologies Limited
| Name | Designation | Experience | Linkedin Profile |
|---|---|---|---|
| Badari Narayan | MD & CEO | 25+ |  |
| Vijaya Gopal Nagaradagadde | Director, Co-founder | 15+ | |
Latest News
Latest Post
Coming soon...
Coming soon...
Frequently Asked Questions
S3V Vascular Technologies Limited unlisted shares are equity shares of the company that are not listed on NSE or BSE and are traded privately.
Yes, S3V Vascular Technologies Limited unlisted shares can be purchased through private market platforms, subject to availability.
Yes, a demat account is required to hold S3V Vascular Technologies Limited unlisted shares.
S3V Vascular Technologies Limited operates in a high-growth healthcare segment but faces regulatory and competitive risks, making it a moderate-risk investment.
Yes, S3V Vascular Technologies Limited unlisted shares can be sold in the secondary market depending on buyer availability.
Yes, as per SEBI regulations, pre-IPO investors are subject to a six-month lock-in period after listing.
If held for more than two years, gains are taxed at 20% with indexation; otherwise taxed as per income slab.
+91-9599071664
amit@unlistedkraft.in